↓ Skip to main content

Upregulation of NETO2 expression correlates with tumor progression and poor prognosis in colorectal carcinoma

Overview of attention for article published in BMC Cancer, December 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
12 Mendeley
Title
Upregulation of NETO2 expression correlates with tumor progression and poor prognosis in colorectal carcinoma
Published in
BMC Cancer, December 2015
DOI 10.1186/s12885-015-2018-y
Pubmed ID
Authors

Liang Hu, Hai-Yang Chen, Jian Cai, Guang-Zhen Yang, Dan Feng, Yan-Xia Zhai, Hui Gong, Chen-Ye Qi, Yu Zhang, Hao Fu, Qing-Ping Cai, Chun-Fang Gao

Abstract

Neuropilin and tolloid-like 2 (NETO2) has been found to be overexpressed in different human cancers, but its expression pattern and clinical relevance in colorectal carcinoma (CRC) remains unknown. Real-time quantitative PCR, western blot and immunohistochemistry analyses were used to analyze the expression of NETO2 in CRC clinical samples. The correlation of NETO2 expression with clinicopathologic features was estimated in a cohort containing 292 patients with primary CRC. Kaplan-Meier and Cox proportional hazards regression analyses were used to assess the prognostic value of NETO2 expression in CRC. The expression of NETO2 was frequently upregulated in CRC clinical samples at both the mRNA and protein levels, and its upregulation was significantly correlated with poor tumor differentiation (p = 0.013), advanced local invasion (p = 0.049), increased lymph node metastasis (p = 0.009), advanced TNM stage (p = 0.041) and increased patient death (p = 0.001). Kaplan-Meier analysis of the complete study cohort revealed that patients with high-NETO2 tumors had a significantly shorter disease-specific survival (DSS) than those with low-NETO2 tumors (p < 0.001). Importantly, high levels of NETO2 protein predicted poor DSS for patients with early stage tumors (p = 0.027) and for those with advanced stage tumors (p = 0.020). Furthermore, multivariate analyses indicated that increased NETO2 expression was an independent unfavorable prognostic factor for patients with early stage tumors (hazard ratio [HR] = 1.937, 95 % CI = 1.107-3.390, p = 0.021) as well as patients with advanced stage tumors (HR = 2.241, 95 % CI = 1.245-4.035, p = 0.007). Our findings suggest that NETO2 upregulation could serve as a potential biomarker for the prediction of advanced tumor progression and unfavorable prognosis in patients with CRC.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 6 50%
Student > Ph. D. Student 4 33%
Other 1 8%
Student > Bachelor 1 8%
Readers by discipline Count As %
Unspecified 6 50%
Agricultural and Biological Sciences 3 25%
Biochemistry, Genetics and Molecular Biology 1 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Medicine and Dentistry 1 8%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 December 2015.
All research outputs
#5,880,016
of 6,865,651 outputs
Outputs from BMC Cancer
#2,483
of 3,144 outputs
Outputs of similar age
#240,279
of 296,126 outputs
Outputs of similar age from BMC Cancer
#117
of 177 outputs
Altmetric has tracked 6,865,651 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,144 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,126 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 177 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.